Famotidine Tablet, Film Coated
Product Images NDC 72865-214

XLcare Pharmaceuticals Inc. offers Famotidine Tablets, USP in a bottle of 100 tablets. Each film-coated tablet contains 20 mg of Famotidine USP, and the usual dosage should be verified in the package insert. Store at 20° to 25°C (68° to 77°F), with excursions allowed to 15° o 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a USP tight, light-resistant container. The medication is manufactured by Ascent Pharmaceuticals, Inc. in Centralslip, NY and made for XLCare Pharmaceuticals, Inc. in Lawrenceville, GA. The prescription drug is available with the NDC number 72865-214-01 and is rx-only.*

This is a description of a medication called Famotidine, which comes in a 180-tablet package. The tablets contain 20mg of Famotidine USP and are film-coated. The medication is prescription-only and the recommended dosage is provided in the package insert. The tablets should be stored within a certain temperature range and in a USP tight container. The medication is manufactured by Ascent Pharmaceuticals and sold by XLCare Pharmaceuticals. The package was last revised on December 21st.*

This is a description of Famotidine Tablets manufactured by XLcare Pharmaceuticals Inc. Famotidine is a medication used to treat and prevent ulcers in the stomach and intestines. Each film-coated tablet contains 20 mg of Famotidine USP. The recommended dosage is available in the package insert. The tablets should be stored between 20°C to 25°C (68°F to 77°F). Dispensing should be done in a tight light-resistant container. The tablets were manufactured by Ascent Pharmaceuticals Inc. for XLCare Pharmaceuticals Inc, located in Lawrenceville, GA.*

This is a description of Famotidine Tablets, USP produced by XLcare Pharmaceuticals Inc. each tablet contains 20mg Famotidin USP, and there are 500 tablets in the package. It is for Rx only and it is advised to see package for full instructions. The tablets should be stored between 20° to 25°C (68° to 77°F) with excursions permitted to 15° o 30°C. They should be dispensed in a USP tight, light-resistant container. It is manufactured by Ascent Pharmaceuticals, Inc for XLCare Pharmaceuticals, Inc.*

XLcare Pharmaceuticals Inc. offers Famotidine Tablets, USP that are prescription medication. Each tablet contains Famotidine USP 40 mg. It is recommended to see the package insert for full prescribing information about the usual dosage. The tablets should be stored in a USP tight, light-resistant container at a temperature of 20° to 25°C (68° to 77°F) with excursions permitted to 15° o 30°C (59° to 86°F). XLcare Pharmaceuticals Inc. manufactured it for Ascent Pharmaceuticals Inc. located in Central slip, NY 11722.*

XLcare Pharmaceuticals Inc. offers Famotidine Tablets with each tablet containing Famotidin USP 40mg. The package contains 180 film-coated tablets that come with information on the recommended dosage. It is recommended to store the medicine at room temperature between 20° to 25°C (68° to 77°F) which can be extended to 15° o 30°C (59° to 86°F) as well. The package is tightly sealed in a light-resistant container as per USP guidelines. The manufacturer is Ascent Pharmaceuticals, Inc. located in Centralslip, NY, and the medicine is sold by XLCare Pharmaceuticals, Inc. based in Lawrenceville, Georgia.*

XLcare Pharmaceuticals Inc. offers Famotidine Tablets, USP through NDC 72865-215-30. Each tablet contains Famotidine USP 40 mg and is a prescription medication. One should refer to the package insert for complete prescribing information on the usual dosage. Store between 20° to 25°C (68° to 77°F) with excursions allowed from 15° o 30°C (59° to 86°F) according to USP Controlled Room Temperature. Dispense in a light-resistant and tight USP container. Ascent Pharmaceuticals, Inc based in Central slip, NY 11722 manufactured it for XLcare Pharmaceuticals, Inc. in Lawrenceville, GA. Rev: 12/21.*

Each film-coated tablet contains 40 mg of Famotidine USP. The usual dosage can be found in the package insert for full prescribing information. The tablets are manufactured by Ascent Pharmaceuticals for XLCare Pharmaceuticals and packaged in bottles of 500 tablets. The NDC code is 72865-215-05. The tablets should be stored at temperatures between 15-30°C (56°-86°F), with excursions permitted. This product is for prescription use only.*

This is a table showing the recommended maximum dosages of Famotidine tablets for adult and pediatric patients weighing 40 kg or more, with moderate or severe renal impairment. The dosages vary based on the patient's creatinine clearance levels. The table also lists the recommended dosages for various indications, including active duodenal ulcer, active gastric ulcer, symptomatic nonerosive GERD, erosive esophagitis diagnosed by endoscopy, and reduction of the risk of recurrence. Dosage adjustments are provided, and an alternate dosage regimen is suggested for certain cases. There are warnings about the safety and effectiveness of the drug in pediatric patients, as well as potential adverse reactions in patients with impaired renal function.*

This is a table showing the serum concentrations of Famotidine in Pediatric and Adult patients. The data is presented using a Sigmoid Eves model, and the serum concentrations associated with a 50% maximum reduction in gastric acid are shown as means = SD. There are separate columns for pediatric patients and adults, including healthy adult subjects and adult patients with upper GI bleeding.*

The text describes a table presenting the percentage of patients with healed duodenal ulcers after two and four weeks of treatment with Famotidine, a medication used to reduce stomach acid production, compared to a placebo group. The table shows that Famotidine was more effective in treating the ulcers than the placebo, with statistically significant differences observed at both week 2 and week 4.*

This is a table presenting the results of two studies conducted on patients with healed gastric ulcers. The first study included 149 patients in the US, while the second study included 294 patients internationally. The patients were given either Famotidine or a placebo at bedtime. The table shows the percentage of patients whose ulcers remained healed over the course of four, six, and eight weeks. The results revealed that Famotidine was more effective in keeping the ulcers healed when compared to the placebo. The percentage of ulcer recurrence was significantly lower in the groups treated with Famotidine as compared to the placebo in both studies.*

The table shows the results of a study on patients who were given either Famotidine or placebo. Famotidine was given at a 20mg dose twice a day or a 40mg dose at bedtime. The study lasted for 6 weeks and involved 149 patients in the Famotidine group and 13 in the placebo group. After 6 weeks, the results showed that 69% of patients taking Famotidine had a positive outcome compared to 62% of patients in the placebo group. The statistical significance of the results was p=0.01 when comparing Famotidine to placebo.*

This is a table showing the percentage of patients who experienced endoscopic healing of erosive esophagitis after taking Famotidine or Placebo medication. The study was conducted in the US and involved 127 patients who were given 40 mg of Famotidine twice daily, 125 patients who were given 20 mg of Famotidine twice daily, and 66 patients who were given Placebo medication. The table shows the percentage of patients who experienced healing after 6 weeks and 12 weeks. The data suggests that Famotidine is more effective than Placebo medication in treating erosive esophagitis. There are also statistical comparisons between the success rates of the different medications.*

This is a table presenting data on patients with erosive esophagitis who participated in an international study. The patients were divided into three groups: those who received famotidine 40 mg twice daily, those who received famotidine 20 mg twice daily, and those who received ranitidine 150 mg twice daily. The data shows the percentage of patients with endoscopic healing of erosive esophagitis at week 6 and week 12 in each group. The table also highlights that the percentage of patients with endoscopic healing was significantly higher with famotidine 20 mg twice daily compared to ranitidine 150 mg twice daily (p=0.05).*